The purpose of this study is to measure the effects of LiQ-NOL supplementation on language production using the Clinical Evaluation of Language Fundamentals test, language sampling using the mean length of utterance test, and speech articulation using the Goldman-Fristoe Test of Articulation.
This is a randomized, double-blind, placebo-controlled clinical study of CoQ efficacy in a crossover design. Patients will be screened, enrolled, and studied in the outpatient clinic of the Thomas Center for Down Syndrome at CCHMC. All patients will be randomly assigned to either a liquid product (LiQ-NOL®) and an identical placebo liquid. Study drug and placebo will be administered twice a day (morning and evening).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months
syrup looks exactly like the Ubiquinol-10 Syrup but has no active ingredients or supplementation
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
To measure the effects of LiQ-NOL on language skills, expressive language ability, and speech articulation.
Time frame: beginning and end of 3 month treatment period
To evaluate the effects of LiQ-NOL on child behavior.
Time frame: beginning and end of 3 month treatment period
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.